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ABSTRACT
Introduction: Rheumatoid arthritis (RA) is a complex multifactorial chronic disease. The importance of human leukocyte 
antigen as a major genetic risk factor for RA was studied worldwide. Although it is widely distributed in different Syrian 
areas, studies of human leukocyte antigen (HLA) alleles’ role are absent. Objective: The aim of our study was to determine 
the association of HLA-DRB1 alleles with the susceptibility and severity of RA in Syria. Patients and methods: Eighty-
six RA patients and 200 healthy controls from Syria were genotyped using polymerase chain reaction with sequence-
speci¿ c primer (PCR-SSP). Anti-CCP antibodies were measured by ELISA. Rheumatoid factor (RF), C-reactive protein 
(CRP), erythrocyte sedimentation rate (ESR), and disease activity score 28 (DAS-28) values were obtained from patients’ 
medical records. DAS-28 was used to assess the clinical severity of the patients. Results: The HLA-DRB1*01, *04, and 
*10 frequencies showed a strong association with the disease susceptibility (OR = 2.29, 95% CI = 1.11–4.75, P = 0.022; 
OR = 3.16, 95% CI = 2.08–4.8, P < 0.0001; OR = 2.43, 95% CI = 1.07–5.51, P = 0.029 respectively), while the frequen-
cies of HLA-DRB1*11, and *13 were signi¿ cantly lower in RA patients than in controls (OR = 0.49, 95% CI = 0.3–0.8, 
P = 0.004; OR = 0.32, 95% CI = 0.15–0.69, P = 0.002, respectively). The other HLA-DRB1 alleles showed no signi¿ cant 
difference. The frequency of anti-CCP antibodies was higher in shared epitope (SE) positive patients compared with 
SE-negative patients (OR = 5.5, 95% CI = 2–15.1, P = 0.00054). DAS-28 of RA patients didn't show signi¿ cant difference 
between the SE negative and the SE positive groups. Conclusion: Our results indicate that HLA-DRB1*01, *04, and *10 
alleles are related with RA, while HLA-DRB1*11 and *13 protect against RA in the Syrian population. 
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INTRODUCTION
Rheumatoid arthritis (RA) is one of the complex immune-
mediated diseases with unknown etiology and an estimated 
population prevalence of 1%.1 It is characterized by chronic 
inflammation, synovitis, pain, and progressive destruction 
of both the articular cartilage and bone leading to functional 
disability.2 The chance of developing the disease is 2–3 times 
more frequent in women than men. The peak age on onset of the 
disease is in the 40s, although it can occur at any age.3 Genetic 
and environmental risk factors play key roles in the disease 
pathogenesis.1,4 The inheritance probability of RA is estimated 
to be around 60%.4,5
The human leukocyte antigen (HLA) is found to be the 
most important genetic risk factor for RA, which accounts 
for 30%1,5 to 50% of overall genetic susceptibility to RA.6 
The shared epitope (SE) hypothesis described the relationship 
between HLA-DRB1 and RA.7,8 HLA-DRB1 alleles encoding 
the SE (DRB1*01, *04, *10, and *14) are associated with 
structural severity of RA and have been more recently related 
with production of anti-citrullinated peptide autoantibod-
ies (anti-CCP).5,6 On the other hand, SE negative genotypes 
(mainly DRB1*11 and *13) provide protection against RA 
susceptibility.6,9
The major relationship of particular HLA alleles with RA 
is not constant in all human populations, different geographi-
cal areas, or among different ethnic groups.1 Despite of the 
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wide distribution of RA in Syria, the HLA-DRB1 studies are 
still absent. Hence, the aim of our study is to determine the 
association of HLA-DRB1 alleles in the disease susceptibility 
and severity in Syria.
PATIENTS AND METHODS
The study was designed as a case-control study. Blood samples 
were obtained from 86 patients (mean age 41.41 ± 10.57 
years; 69 women, 17 men) admitted to the Department of 
Rheumatology, Ibn Na¿ s Hospital, Almowasat and Al-Assad 
Hospitals, Damascus University, between January 2010 and 
September 2011. All patients ful¿ lled the American College 
of Rheumatology (ACR) criteria.10 Two hundred healthy un-
related volunteers (mean age 40.21 ± 10.11 years; 160 women 
and 40 men) matched by age, gender, and ethnic origin were 
allocated as controls. An informed consent was obtained from 
all patients and healthy individuals. The project was approved 
by the Ethical Committee of Damascus University.
The detection of anti-CCP IgG antibodies was performed 
using second-generation ELISA kit (Euroimmun, Lübeck, 
Germany). Serum samples presenting results > 5 RU/mL were 
considered to be positive for anti-CCP antibodies. Rheumatoid 
factor (RF), C-reactive protein (CRP), erythrocyte sedimenta-
tion rate (ESR), and disease activity score 28 (DAS-28) values 
were adopted from patients’ medical records. DAS-28 was used 
to assess the clinical severity of the patients.11 Genomic DNA 
of patients with RA (n = 86) and healthy controls (n = 200) 
were isolated from 300 L aliquots of peripheral anticoagulated 
venous blood samples by using the High Pure PCR Template 
Preparation Kit (Roche, Mannheim, Germany). Genotyping 
of HLA-DRB1 was performed by polymerase chain reaction 
with sequence-speci¿ c primers (PCR-SSP) using Micro SSPT 
Generic HLA Class II (DRB) (One Lambda Inc., CA, USA).
Odds ratio (OR) and 95% con¿ dence interval (95% CI) 
were calculated to estimate the strengths of the associations. 
Chi-squared and Student’s t-test were used in the statistical 
analysis. Differences were considered to be signi¿ cant at 
P < 0.05.
RESULTS
Demographic data and clinical ¿ ndings of 86 RA patients 
diagnosed according to modi¿ ed ACR criteria are given in 
Table 1. Frequencies of HLA-DRB1 alleles of RA patients 
and normal individuals are summarized in Table 2. In RA 
patients, HLA-DRB1 *01, *04, and *10 allele frequencies 
were higher than controls (OR = 2.29, 95% CI = 1.11–4.75, 
Table 1
Demographic and clinical characteristics of patients with 
rheumatoid arthritis 
Characteristics RA (n = 86)
Age, mean (± SD) years 41.41 (10.57) 
Disease duration, mean (± SD) years 11.26 (6.25) 
Women 69 (80.23%)
Men 17 (19.77%)
Women:Men ratio 4:1
RF positive patients 55 (63.95%)
Anti-CCP positive patients 52 (60.46%)
Anti-CCP (RU/mL) 110.82 (105.12)
CRP (mg/L) 31.14 (38.4)
ESR (mm/hr) 56.71 (29.67)
DAS-28, mean (SD) 6.12 (1.4)
Values are mean (SD) or number (%) unless otherwise indicated.
n: number of RA patients; SD: standard deviation; RF: rheumatoid factor; Anti-CCP: anti-citrullinated 
peptide antibodies; RU: relative units; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; 
DAS-28: disease activity score 28.
P = 0.022; OR = 3.16, 95% CI = 2.08–4.8, P < 0.0001; and 
OR = 2.43, 95% CI = 1.07–5.51, P = 0.029, respectively). In 
contrast, DRB1 *11 and *13 alleles were more frequent in 
controls (OR = 0.49, 95% CI = 0.3–0.8, P = 0.004; OR = 0.32, 
95% CI = 0.15–0.69, P = 0.002, respectively). The allele 
frequency differences of DRB1*03, *07, *08, *09, *12, *14, 
*15, and *16 were not statistically signi¿ cant (95% CI of *16 
overlapped 1). Compared with controls, frequencies of SE posi-
tive alleles (the sum of DRB1*01, *04, *10, *14) were higher 
in RA patients (OR = 3.41, 95% CI = 2.35–4.95, P < 0.0001). 
Anti-CCP antibody was present in 60.46% and RF in 
63.95% of the RA patients. Frequencies of anti-CCP antibod-
ies and RF were higher in SE-positive patients compared to 
SE-negative patients (OR = 5.5, 95% CI = 2–15.1, P < 0.001; 
OR = 5.45, 95% CI = 2–14.87, P < 0.001, respectively) 
(Table 3). 
Disease severity presented by DAS-28 values showed no 
signi¿ cance between SE negative and SE positive RA patients 
(Figure 1).
DISCUSSION
Different literatures investigated the biogeographic distribution 
of RA-DRB1 alleles in various ethnicities and races around 
the world.1,5,12 HLA-DRB1*04 allele has been reported to be 
linked to RA in many populations.13–25 DRB1*04 was frequent 
in RA patients in Morocco26 and Zahedan southeast Iran,27 but 
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Table 3
Association of HLA-DRB1 shared epitopes alleles with anti-
CCP and rheumatoid factor antibodies in rheumatoid arthritis 
patients (n = 86) 
SE status SE positive (n = 61)
SE negative 
(n = 25)
OR 
(95% CI) P
Anti-CCP 
positive 44 (72.13%) 8 (32%)
5.5 
(2–15.1) 0.00054
Anti-CCP 
negative 17 (27.87%) 17 (68%)
RF positive 46 (73.77%) 9 (32%) 5.45 (2–14.87) 0.00055
RF negative 15 (26.23%) 16 (68%)
Values are number (%) unless otherwise indicated. Presence of anti-CCP antibodies and RF in 
SE-positive or SE-negative RA patients was compared using the chi-square test. Differences were 
considered to be signiﬁ cant at P < 0.05.
SE: shared epitopes; OR: odds ratio; 95% CI: conﬁ dence interval at 95%. 
Table 2
The distribution of HLA-DRB1 allele frequencies in RA patients and controls 
Genotype
HLA-DRB 1
RA (2n = 172) Controls (2n = 400) Statistical analysis
n AF (%) n AF (%) OR (95% CI) P 
DRB1*01 15 9.0 16 4 2.29 (1.11–4.75) 0.022
DRB1*03 13 7.8 38 10 0.78 (0.40–1.50) 0.455
DRB1*04 60 36.1 58 15 3.16 (2.08–4.80) < 0.0001
DRB1*07 12 7.2 44 10 0.61 (0.31–1.18) 0.137
DRB1*08 2 1.2 7 1.5 0.66 (0.14–3.21) 0.605
DRB1*09 1 0.6 2 0.5 1.16 (0.10–12.92) 0.901
DRB1*10 12 7.2 12 3 2.43 (1.07–5.51) 0.029
DRB1*11 24 14.5 99 25 0.49 (0.30–0.80) 0.004
DRB1*12 0 0.0 6 1.5 0.00 0.106
DRB1*13 8 4.8 53 13.5 0.32 (0.15–0.69) 0.002
DRB1*14 10 6.0 23 6 1.01 (0.47–2.17) 0.976
DRB1*15 10 6.0 37 9.5 0.61 (0.29–1.25) 0.170
DRB1*16+ 5 3.0 3 0.5 3.96 (0.94–16.77) 0.044
SE positive 97 56.4 110 30.5 3.41 (2.35–4.95) <0.0001
Values are number (%) unless otherwise indicated. 
AF: allele frequency; SE positive: the sum of DRB1*01, *04, *10, and *14 alleles; OR: odds ratio; 95% CI: conﬁ dence interval at 95%. HLA frequencies observed in patients and controls were compared using 
the chi-square test. Differences were considered signiﬁ cant at P < 0.05.
+ Not signiﬁ cant because 95% CI of *16 overlapped 1.
surprisingly with no signi¿ cance. On the other hand, Peruvian28 
and Mexican American29 populations showed no signi¿ cant 
correlation between HLA-DRB1*04 and RA susceptibility. 
Other alleles were associated with RA proneness as DRB*01 
in Brazilians,30 Mexicans,31 Spanish,14 Italians,20 French,24 
Turkish,25,32 Finnish,17 and Japanese;33 DRB1*09 in Turkish,25 
Malaysians,34 and Koreans;35 DRB1*10 in Brazilians,30 
Iranians,27 Saudi Arabians,16 Taiwanese,36 Asians,37 and African 
Figure 1
Relation between shared epitopes and DAS-28 in 86 rheuma-
toid arthritis patients.
The DAS-28 values were compared between SE negative and 
SE positive RA patients using Student’s t-test. Differences were 
considered to be signi¿ cant at P < 0.05.
n: number of RA patients carrying the alternative genotype.
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Americans,22 and DRB1*14 in Peruvians,28 Ecuadorians,38 and 
Mexican Americans.29 Uncommonly, HLA-DRB1*08 was re-
ported for its association with RA in Saudi Arabians16 and HLA-
DRB1*15 in Japanese.33 In accordance to the nearby populations 
(Middle Eastern and Mediterranean), our results showed that RA 
susceptibility is predominantly associated with DRB1*01, *04, 
and *10 alleles. Albeit not signi¿ cant, DRB1*09, *14, and *16 
were more frequent in RA patients than controls.
The protective effect of certain HLA-DRB1 alleles against 
RA has been reported in several reviews5,12,39,40 and revealed 
in different populations. HLA-DRB1*03 was informed to be 
protective against RA in Iranians27 and Asians;19 DRB1*06 in 
Saudis;16 DRB1*07 in Slovakians,23 Finnish,17 and Tunisians;13 
DRB1*08 in Mexican Americans;29 DRB1*11 in Peruvian28 
and African Americans;22 whereas DRB1*13 in Turkish,25,32 
Finnish,17 Asians,19 and Slovakians.23 In this study HLA-
DRB1*11 and *13 were negatively associated with RA reÀ ect-
ing a probable protective effect in our population.
The relation between the SEs and the severity of RA has not 
been clearly veri¿ ed.41 The DRB1*0401 allele is indicated to 
increase the severity of RA in northern Europe,42 Netherlands,43 
northern Italy,44 and Caucasians;45,46 whereas DRB1*0405 al-
lele is speci¿ ed in Korea.47 In contrary, our study showed no 
signi¿ cant correlation of disease severity, assessed by mean 
DAS-28 values, between the SE positive and SE negative pa-
tients. These results comply with studies carried out in Turkey32 
and Greece.48 Our study supported previously reported relation-
ship of SE positive alleles in the productions of anti-CCP and 
RF sero-positivity.5,6,30,43 Even the less, results in this study may 
not reÀ ect the relationship between HLA-DRB1 and disease 
severity because of limited number of patients. 
Our study was limited by the inability to perform four-
digit subtyping of all DRB1 alleles. However, a signi¿ cant 
relation between SE-containing main alleles (the sum of 
DRB1*01, *04, *10, and *14) in patients with RA was resolute 
(OR = 3.41, 95% CI = 2.35–4.95, P < 0.0001).
In conclusion, HLA-DRB1*01, *04, and *10 alleles were 
identi¿ ed as related with RA and HLA-DRB1*11 and *13 were 
detected as protective in our population. No signi¿ cance was 
observed between SEs alleles and RA severity.
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seguem: DRB*01 em brasileiros,30 mexicanos,31 espanhóis,14 
italianos,20 franceses,24 turcos,25,32 ¿ nlandeses17 e japoneses;33 
DRB1*09 em turcos,25 malaios34 e coreanos; 35 DRB1*10 em 
brasileiros,30 iranianos,27 sauditas,16 taiwaneses,36 asiáticos37 e 
afro-americanos;22 e DRB1*14 em peruanos,28 equatorianos38 
e méxico-americanos.29 Houve raros relatos da associação de 
AR com HLA-DRB1*08 em sauditas16 e com HLA-DRB1*15 
em japoneses.33 À semelhança das populações vizinhas 
(Oriente Médio e Mediterrâneo), nossos resultados mostraram 
que a suscetibilidade à AR está predominantemente asso-
ciada aos alelos DRB1*01, *04 e *10. Embora de maneira 
não signi¿ cativa, os alelos DRB1*09, *14 e *16 foram mais 
frequentes em pacientes com AR do que em controles.
O efeito protetor de certos alelos HLA-DRB1 contra AR 
foi relatado em várias revisões5,12,39,40 e mostrado em diferentes 
populações. As seguintes relações de proteção contra AR foram 
relatadas: alelo HLA-DRB1*03 em iranianos27 e asiáticos;19 
DRB1*06 em sauditas;16 DRB1*07 em eslovacos,23 ¿ nlan-
deses17 e tunisianos;13 DRB1*08 em méxico-americanos;29 
DRB1*11 em peruanos28 e afro-americanos;22 e DRB1*13 em 
turcos,25,32 ¿ nlandeses,17 asiáticos19 e eslovacos.23 Neste estudo, 
os alelos HLA-DRB1*11 e *13 associaram-se negativamente 
com AR, reÀ etindo provável efeito protetor na população síria 
estudada.
A relação entre os ECs e a gravidade da AR ainda não foi 
esclarecida.41 Há relatos de que o alelo DRB1*0401 aumente a 
gravidade da AR no norte da Europa,42 na Holanda,43 no norte 
da Itália44 e em caucasianos,45,46 enquanto o alelo DRB1*0405 
é especí¿ co da Coreia do Sul.47 Por outro lado, nosso estudo 
mostrou não haver correlação signi¿ cativa da gravidade da 
doença, avaliada pelo DAS-28, com pacientes EC-positivos 
e EC-negativos. Tais resultados concordam com estudos con-
duzidos na Turquia32 e na Grécia.48 Nosso estudo con¿ rmou o 
relato anterior de relação entre alelos EC-positivos e a produção 
de anti-CCP e soropositividade para FR.5,6,30,43 No entanto, os 
resultados deste estudo podem não reÀ etir a relação entre os 
alelos HLA-DRB1 e a gravidade da doença devido ao número 
limitado de pacientes. 
Nosso estudo foi limitado pela impossibilidade de realizar 
subtipagem de 4 dígitos de todos os alelos DRB1. Entretanto, 
encontrou-se relação signi¿ cativa entre os principais alelos 
contendo EC (a soma de DRB1*01, *04, *10 e *14) em pa-
cientes com AR (OR = 3,41, IC 95% = 2,35–4,95, P < 0,0001).
Concluindo, identi¿ cou-se uma relação dos alelos HLA-
DRB1*01, *04 e *10 com AR, tendo os alelos HLA-DRB1*11 
e *13 sido identi¿ cados como protetores na população síria 
estudada. Não se observou signi¿ cância entre os alelos com 
ECs e gravidade da AR. 
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